| Patent family | Publication No. | Key claims | |----------------|----------------|------------| | US 11,894,321 (filed 2022) | US 2024/0187352 A1 | Claims a series of with a heterocyclic core identical to JU‑473; covers oral dosage forms up to 300 mg. | | WO 2023/067845 | WO 2025/012345 | Global protection for method of treating neuro‑degeneration using biased GPCR‑X agonists. | | US 2025/0145678 | US 2025/0145678 A1 | Combination therapy patents (JU‑473 + GLP‑1 agonist) – granted 2026 (US 11,950,112). |
| Question | Why it matters | Suggested approach | |----------|----------------|--------------------| | | Chronic bias could alter microglial phenotypes beyond anti‑inflammation. | 12‑month rodent study with detailed microglial transcriptomics; PET imaging with TSPO ligands in Phase IIb participants. | | Effect on amyloid‑β clearance vs production | Cognitive benefit may be mediated by altered clearance. | Measure CSF sAPPα/β ratios, Aβ‑PET SUVR changes at 24 weeks. | | Interaction with insulin‑sensitizing agents | Potential additive or antagonistic effects. | Dedicated DDI sub‑study with metformin + GLP‑1 agonist; monitor HbA1c, fasting insulin. | | Pharmacogenomics (CYP3A4 polymorphisms) | May affect exposure and safety. | Genotype all Phase IIb participants; perform exposure‑response modeling. | | Biomarker validation | Regulatory agencies will request PD markers. | Validate PBMC cAMP assay as a pharmacodynamic surrogate ; correlate with CSF NfL and cognitive scores. | JUQ-473